Pharmacology - Endocrinology Flashcards
Metformin
- *Indications:** Diabetes mellitus, PCOS
- *MOA:** Biguanide: Insulin sensitiser → decreases gluconeogenesis, increases peripheral glucose use, decreases LDL and VLDL
- *S/E’s:** Lactic acidosis, GI upset: N, V + D; anorexia/weight loss
- *CI’s:** Caution in renal/hepatic impairment, heart failure, contrast media, general anaesthesia, recent MI, ketoacidosis
- *Interactions:**
- *Other info:** Renally excreted - reduce dose if renal impairment or avoid if GFR v.low. Cannot cause hypos
Pioglitazone
- *Indications:** Type 2 DM (alone or combined with metformin or sulfonylurea)
- *MOA:** Thiazolidinedione - peripheral insulin sensitiser, PPAR gamma ligand - a nuclear receptor involved in glucose and lipid homeostatsis
- *S/E’s:** GI disturbance, weight gain, oedema, hepatotoxicity, may exacerbate HF
- *CI’s:** Heart/liver failure, with insulin use or ACS
- *Interactions:**
- *Other info:** Very protein bound, hepatic metabolism therefore monitor LFTs
Sulfonylureas
Short acting –> Gliclazide, Tolbutamide, Glipizide
Long acting –> Glibenclamide
- *Indications:** Type 2 DM
- *MOA:** Sulfonylureas: insulin secretagogues –> block hyperpolarising K+ channel on beta cells –> depolarisation and insulin release
- *S/E’s:** Hypoglycaemia - can be prolonged, weight gain, GI upset, headache
- *CI’s:** Acute porphyria, severe liver/renal impairment
- *Interactions:** Effects increased by: sulphonamides, trimethoprim, NSAIDs, warfarin, fibrates
- *Other info:** Renally excreted; v. albumin bound; caution in elderly with reduced renal function; avoid long acting (glibenclamide) in the elderly
Nateglinide
Repaglinide
- *Indications:** Type 2 DM in combination with metformin
- *MOA:** Meglitinides - insulin secretagogues, block hyperpolarising K+ channels
- *S/E’s:** Hypoglyaemia
- *CI’s:** Ketoacidosis
- *Interactions:**
- *Other info:** Very short acting –> reduced risk of hypo; give before a meal
Exenatide
Liraglutide
- *Indications:** Type 2 DM
- *MOA:** Insulin secretagogue: GLP-1 analogue –> increased insulin secretion and sensitisation
- *S/E’s:** GI upset; hypoglycaemia
- *CI’s:** Ketoacidosis, severe GIT disease
- *Interactions:**
- *Other info:** Give by SC injection
Sitagliptin
Vildagliptin
Indications: Type 2 DM
MOA: Insulin secretagogues: dipeptidylpeptidase-4 inhibitor, DPP-4 breaks down endogenous GLP-1
S/E’s: GI upset, hypoglycaemia
CI’s: Ketoacidosis, discontinue if signs of severe acute pancreatitis
Interactions:
Other info:
Acarbose
Indications: DM inadequately controlled by diet
MOA: Intestinal alpha-glucosidase inhibitor: delays carb absorption –> decreases post prandial blood glucose. Little effect on fasting glucose
S/E’s: Flatulence, loose stools/diarrhoea, abod pain, bloating, hepatotoxicity (rare)
CI’s: IBD, liver impairment
Interactions:
Other info: Monitor LFTs
Levothyroxine
Indications: Hypothyroidism
MOA: Synthetic form of thyroxine
S/E’s: Precipitation of HF, osteopenia, AF. Over Rx –> hyperthyroidism
CI’s: Thyrotoxicosis; caution in elderly, cardio disorders e.g. HTN, MI etc
Interactions:
Other info: In the elderly start low and go slow
Carbimazole
Propythiouracil (PTU)
Indications: Hyperthyroidism
MOA: Thionamides - thyroperoxidase inhibitors, prevent iodination of tyrosine = reduced T4/T3 synthesis. Carbimazole is a pro-drug converted to methimazole
S/E’s: Hypersensitivity, hepatitis, GI disturbance, agranulocytosis - often transient and benign
CI’s: Severe blood disorders. Use PTU in pregnancy and children. If there is tracheal compression do sx
Interactions:
Other info: PTU reserved for those intolerant of carbimazole due to it’s increased risk of hepatitis. Titrate to normal TSH or use a block and replace regime
Radioiodine: I131
Indications: Thyrotoxicosis
MOA: Radioiodine is localised to the thyroid causing gland destruction
S/E’s: Hypothyroidism = need lifelong levothyroxine. Can precipitate a thyroid storm
CI’s:
Interactions:
Other info: Stop thionamide before use
Dopamine agonists
Short acting: Bromocriptine
Long acting: Cabergoline, Pergolide
- *Indications: **Galactorrhoea, prolactinomas (Parkinson’s) Bromocriptine also inhibits GH so can be used for acromegaly
- *MOA:** Ergot-derived DA agonists
- *S/E’s:** Fibrosis, GI upset, nausea, postural hypotension, drowsiness, neuropsych syndromes e.g. dyskinesia
- *CI’s:** CVS disease, prophyria, psychosis
- *Interactions:** Levels increased by: octreotide, macrolides, dobutamine
- *Other info:** Monitor heart with echo
Octreotide
Lanreotide
Somatostatin analogues
- *Indications: **Acromegaly, Carcinoid syndrome
- *MOA:** Somatostatin analogues
- *S/E’s:** Diarrhoea, gallstones
- *CI’s:** Monitor TFTs + LFTs
- *Interactions:** Decreased requirement for antidiabetics
- *Other info:** Octreotide = TDS, Lanreotide = monthly
Pegvisomant
Indications: Acromegaly
MOA: GH receptor antagonist
S/E’s: GI upset, raised LFTs
CI’s: Caution in liver disease + DM
Interactions:
Other info:
Metyrapone
Indications: Can be used in Cushing’s syndrome that is not amenable to surgery, also used pre-surgery
MOA: Competitive inhibitor of 11-beta-hydroxylase in the adrenal cortex–> results in the inhibition of cortisol (+ to some extent aldosterone) production
S/E’s: GI upset, dizziness, headache
CI’s: Adrenocortical insufficiency, use with caution in hepatic impairment
Interactions:
Other info:
Cinacalcet
Indications: Secondary hyperparathyroidism in ESRF, can also use in 1º hyperPTH or parathyroid carcinoma
MOA: Calcimimetic → decreased PTH secretion
S/E’s: N+V, dizziness
CI’s: Measure serum Ca before starting Rx then monitor during Rx. Caution in mod-severe hepatic impairment
Interactions:
Other info: